Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

CBT Pharmaceuticals doses first patient in Phase l/ll trial of CBT-101

Hepatocellular carcinoma in an individual who was hepatitis C positive. Credit: Ed Uthman.

Go Top